CRISPR Therapeutics (CRSP) director awarded 13,000-share stock option grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

CRISPR Therapeutics AG director Douglas A. Treco received a stock option grant covering 13,000 common shares. The option has an exercise price of $51.84 per share and was awarded at no purchase cost to him on the grant date.

The option expires on June 5, 2036. According to the vesting terms, it becomes exercisable in 12 equal monthly installments, with the first vesting on June 30, 2026 and the final installment vesting on the earlier of the one-year anniversary of the grant date or the date of the 2027 Annual Meeting.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Treco Douglas A

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	13,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 13,000 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Option grant size: 13,000 shares Exercise price: $51.84 per share Expiration date: June 5, 2036 +3 more

6 metrics

Option grant size 13,000 shares Stock Option (Right to Buy) granted to director

Exercise price $51.84 per share Conversion or exercise price of granted options

Expiration date June 5, 2036 Expiration of stock option grant

Vesting start June 30, 2026 First monthly installment vests

Vesting schedule length 12 monthly installments Equal monthly vesting following grant date

Shares after transaction 13,000 options Total options held from this grant after transaction

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, exercise price, vesting, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

exercise price financial

"conversion_or_exercise_price: 51.8400"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"the options will vest and become exercisable in 12 equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Annual Meeting financial

"the last installment vests on the earlier of ... or (ii) the date of the 2027 Annual Meeting"

A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/09/2026 - 05:40 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Treco Douglas A

(Last)

(First)

(Middle)

C/O CRISPR THERAPEUTICS

105 WEST FIRST STREET

(Street)

BOSTON

MASSACHUSETTS

02127

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$51.84	06/05/2026		A		13,000		⁽¹⁾	06/05/2036	Common Shares	13,000	$0	13,000	D

Explanation of Responses:

1. Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.

	/s/ Elizabeth Ryland Waldinger	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did CRISPR Therapeutics (CRSP) director Douglas Treco report?

Douglas A. Treco reported receiving a stock option grant for 13,000 common shares. The option was awarded at no purchase cost and reflects a compensation-related acquisition rather than an open-market share purchase or sale.

What is the exercise price of Douglas Treco’s new CRISPR Therapeutics (CRSP) options?

The granted stock options have an exercise price of $51.84 per share. This means Treco can buy up to 13,000 CRISPR Therapeutics common shares at $51.84 if and when the options vest and are exercised.

When do Douglas Treco’s CRISPR Therapeutics (CRSP) options start and finish vesting?

The options start vesting on June 30, 2026, in 12 equal monthly installments. The final installment vests on the earlier of the one-year anniversary of the grant date or the date of CRISPR Therapeutics’ 2027 Annual Meeting.

When do Douglas Treco’s CRISPR Therapeutics (CRSP) stock options expire?

The stock options granted to Douglas A. Treco expire on June 5, 2036. After that expiration date, any unexercised portion of the 13,000-share option can no longer be used to buy CRISPR Therapeutics common shares.

Is Douglas Treco’s CRISPR Therapeutics (CRSP) Form 4 transaction a market buy or sell?

The Form 4 shows a grant, classified as a “Grant, award, or other acquisition.” It is a compensation-related award of options, not an open-market purchase or sale of CRISPR Therapeutics common shares.

How many CRISPR Therapeutics (CRSP) options does Douglas Treco hold after this grant?

Following this transaction, Douglas A. Treco holds 13,000 stock options directly from this award. These options each relate to one common share and follow the specified vesting schedule and 2036 expiration date.